MSFrontier

Disproven

Methylphenidate: improve symptoms or function in MS (type not specified)

MS (type not specified) · Fatigue / wakefulness

Placebo-controlled phase 3 trials missed their main goal, and none succeeded. This applies to this patient group only.

Trials
3
Running now
0
Controlled phase 2/3 trials
3
People in controlled trials
261

Deciding trials (phase 3): 0 met, 1 did not.

Other linked trials: 2

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • TRIUMPHANT-MSdecides the statusMissed main goal

    Phase 3 · 2017 · Placebo-controlled · MSFT-NCT03185065

    The estimated mean values of MFIS total scores at baseline and the maximal tolerated dose were as follows: 51·3 (95% CI 49·0-53·6) at baseline, 40·6 (38·2-43·1) with placebo, 41·3 (38·8-43·7) with amantadine, 39·0 (36·6-41·4) with modafinil, and 38·6 (36·2-41·0) with methylphenidate (p=0·20 for the overall medication effect in the linear mixed-effect regression model).

    Read by software from the paper's abstract
  • Methylphenidate to Improve Balance and Walking in MSdecides the statusNo result found

    Phase 2/3 · 2013 · Placebo-controlled · MSFT-NCT01896700

Other linked trials: 2

These linked trials do not set the status.

  • MSNo result found

    Phase 2 · 2012 · Placebo-controlled

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-28Status changed from Results pending to Disproven
  • 2026-10-27First listed as Results pending

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error